How do you choose between naltrexone (oral vs extended-release injectable) and baclofen for alcohol use disorder in compensated alcohol-associated cirrhosis with thrombocytopenia after acamprosate nonresponse, and what monitoring/stop criteria make you comfortable continuing therapy?